拓扑异构酶Ⅱα在前列腺癌中的研究进展

牛吉瑞; 纪志刚

doi:10.13201/j.issn.1001-1420.2019.02.018

拓扑异构酶Ⅱα在前列腺癌中的研究进展

牛吉瑞¹,
纪志刚^2, ,

- 1. 黑龙江省医院泌尿外科(哈尔滨, 150036);
- 2. 中国医学科学院北京协和医学院北京协和医院泌尿外科
基金项目:
黑龙江省卫生计生委科研课题(编号2017-481)

详细信息

通讯作者: 纪志刚,E-mail:jzg1129@medmail.com.cn

中图分类号: R737.25

收稿日期: 2017-09-19

Update of topoisomerase Ⅱα for prostate cancer

NIU Jirui¹,
JI Zhigang^2, ,

- 1. Department of Urology, Heilongjiang Provincial Hospital, Harbin, 150036, China;
- 2. Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

More Information

Corresponding author: JI Zhigang, E-mail: jzg1129@medmail.com.cn

Received Date: 19 September 2017

摘要

摘要: 拓扑异构酶Ⅱα(TOP2α)是控制DNA拓扑状态和细胞增殖的一类酶蛋白。它可能成为一种新型前列腺癌(PCa)的标记物,同时可以较好地评估PCa患者的预后。将有助于预测PCa预后、评估疗效及降低医疗成本。本文将对该标记物的特点及临床应用作一综述。
- 前列腺癌 /
- 肿瘤标记物 /
- 拓扑异构酶Ⅱα
Abstract: TopoisomeraseⅡα, a zymoprotein, controls DNA topological structure and cell cycle progression.This enzyme may be a tumor marker of cell proliferation in prostate cancer.It evaluates the prognosis of prostate cancer very well, so it is helpful for us to prognosticate prostate cancer, evaluate the treatment and reduce the medical cost.This article reviews the characteristic of the marker and its clinical application.
- prostate cancer /
- tumor marker /
- topoisomerase Ⅱα

HTML全文

参考文献(25)

[1]	于茵, 牛吉瑞, 李红松.前列腺癌标记物的现状研究[J].中国男科学杂志, 2014, 28 (11): 70-72.
[2]	Baade P D, Youlden D R, Cramb S M, et al.Epidemiology of prostate cancer in the Asia-Pacific region[J].Prostate Int, 2013, 1 (2): 47-58.
[3]	年新文, 任善成, 许传亮, 等.前列腺早期诊断标记物的研究进展[J].临床泌尿外科杂志, 2016, 31 (9): 852-856.
[4]	Mirski S E, Bielawski J C, Cole S P.Identification of functional nuclear export sequences in human topoisomeraseⅡαandβ[J].Biochem Biophs Res Commun, 2003, 306 (4): 905-911.
[5]	Amirnasr A, Verdijk R M, van Kuijk P F, et al.Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors[J].PLoS One, 2017, 12 (8): e0183155.
[6]	Murphy A J, Hughes C A, Barrett C, et al.Low-Level TOP2A Amplification in Prostate Cancer Is Associated with HER2Duplication, Androgen Resistance and Decreased Survival[J].Cancer Res, 2007, 67:2893-2898.
[7]	Wang J, Xu B, Yuan P, et al.TOP2A amplification in breast cancer is a predictive marker of anthracyclinebased neoadjuvant chemotherapy efficacy[J].Breast Cancer Res Treat, 2012, 135 (2): 531-537.
[8]	Hasby E A, Saied E M.Immunohistochemical expression of topoisomeraseⅡalpha and Her-2/neu in prostatic carcinoma and benign prostatic hyperplasia[J].J E-gypt Natl Canc Inst, 2008, 20 (2): 158-167.
[9]	Tsavaris N, Lazaris A, Kosmas C, et al.Topoisomerase IandⅡαprotein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy[J].Cancer Chemother Pharmacol, 2009, 64 (2): 391-398.
[10]	O'Connor J K, Hazard L J, Avent J M, et al.TopoisomeraseⅡalpha expression correlates with diminished disease-free survival in invasive breast cancer[J].Int J Radiat Oncol Biol Phys, 2006, 65 (5): 1411-1415.
[11]	梁婷婷, 王永坤, 王尧.拓扑异构酶2α受抑癌基因p53的调控并调节前列腺癌细胞的增殖能力[J].中国实验诊断学, 2017, 21 (7): 1261-1264.
[12]	王全志, 郭艳风, 韩芳毅, 等.p53与DNA拓扑异构酶Ⅱα在胆囊腺癌中的表达及临床意义[J].南昌大学学报 (医学版), 2017, 57 (1): 30-34.
[13]	王晶, 佟秀琴.程序性死亡受体1配体、拓扑异构酶Ⅱα及p16蛋白在子宫颈癌中的表达及其意义[J].肿瘤研究与临床, 2017, 29 (4): 235-240.
[14]	SchrderF H, Hugosson J, Roobol M J, et al.Screening and prostate-cancer mortality in a randomized European study[J].N Engl J Med, 2009, 360 (13): 1320-1328.
[15]	Pienta K J, Redman B, Hussain M, et al.PhaseⅡevaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate[J].JClin Oncol, 1994, 12 (10): 2005-2012.
[16]	de Resende M F, Vieira S, Chinen L T, et al.Prognostication of prostate cancer based on TOP2Aprotein and gene assessment:TOP2Ain prostate cancer[J].J Transl Med, 2013, 11:36.
[17]	Hughes C, Murphy A, Martin C, et al.TopoisomeraseⅡ-a lphaexpression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma[J].J Clin Pathol, 2006, 59 (7): 721-724.
[18]	牛吉瑞, 于茵, 邢兆辉, 等.前列腺癌中拓扑异构酶Ⅱα的表达及意义[J].中国实用医药, 2017, 12 (26): 35-36.
[19]	Faggad A, Darb-Esfahani S, Wirtz R, et al.TopoisomeraseⅡa mRNA and protein expression in ovarian carcinoma:correlation with clinicopathological factors and prognosis[J].Mod Pathol, 2009, 22 (4): 579-588.
[20]	Schaefer-Klein J L, Murphy S J, Johnson S H, et al.Topoisomerase 2Alpha Cooperates with Androgen Receptor to Contribute to Prostate Cancer Progression[J].PLoS One, 2015, 10 (11): e0142327.
[21]	LabbéD P, Sweeney C J, Brown M, et al.TOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup[J].Clin Cancer Res, 2017, 23 (22): 7072-7083.
[22]	Bromberg K D, Burgin A B, Osheroff N.A two-drug model for etoposide action against human topoisomeraseⅡalpha[J].J Biol Chem, 2003, 278 (9): 7406-7412.
[23]	朱永锋.多西他赛/米托蒽醌联合泼尼松治疗激素抵抗性前列腺癌的临床研究[J].中国临床药理学杂志, 2015, 31 (9): 728-730.
[24]	邵牧民, 徐华, 余学问, 等.基底型乳腺癌中拓扑异构酶Ⅱα基因状态分析[J].临床与实验病理学杂志, 2010, 26 (4): 421-424.
[25]	Monger A, Boonmuen N, Suksen K, et al.Inhibition of TopoisomeraseⅡαand Induction of Apoptosis in Gastric Cancer Cells by 19-TrⅡsopropyl Andrographolide[J].Asian Pac J Cancer Prev, 2017, 18 (10): 2845-2851.